Capital Fund Management S.A. Purchases 4,300 Shares of ICU Medical, Incorporated (ICUI)

Capital Fund Management S.A. raised its holdings in shares of ICU Medical, Incorporated (NASDAQ:ICUI) by 238.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 6,100 shares of the medical instruments supplier’s stock after purchasing an additional 4,300 shares during the period. Capital Fund Management S.A.’s holdings in ICU Medical were worth $1,791,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mackay Shields LLC purchased a new position in ICU Medical during the 2nd quarter valued at about $205,000. Eagle Boston Investment Management Inc. bought a new stake in shares of ICU Medical in the 1st quarter valued at about $206,000. CIBC Asset Management Inc bought a new stake in shares of ICU Medical in the 2nd quarter valued at about $209,000. LPL Financial LLC bought a new stake in shares of ICU Medical in the 1st quarter valued at about $218,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of ICU Medical in the 2nd quarter valued at about $230,000. 74.29% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:ICUI traded up $1.01 during trading on Friday, reaching $273.65. The stock had a trading volume of 216,234 shares, compared to its average volume of 157,376. The stock has a market capitalization of $5.79 billion, a P/E ratio of 49.57 and a beta of 0.41. ICU Medical, Incorporated has a one year low of $180.45 and a one year high of $321.70.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 9th. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.82 by $0.84. The company had revenue of $360.46 million during the quarter, compared to analysts’ expectations of $337.60 million. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. ICU Medical’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the business earned $0.76 EPS. Equities analysts expect that ICU Medical, Incorporated will post 7.6 earnings per share for the current fiscal year.

In related news, VP Virginia Ruth Sanzone sold 787 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $303.12, for a total value of $238,555.44. Following the completion of the sale, the vice president now directly owns 1,367 shares in the company, valued at approximately $414,365.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Thomas D. Mccall sold 11,133 shares of ICU Medical stock in a transaction that occurred on Friday, August 24th. The stock was sold at an average price of $302.56, for a total transaction of $3,368,400.48. Following the completion of the sale, the vice president now owns 3,018 shares of the company’s stock, valued at $913,126.08. The disclosure for this sale can be found here. Insiders sold a total of 711,920 shares of company stock valued at $202,651,956 over the last quarter. 12.50% of the stock is owned by company insiders.

A number of research firms have recently weighed in on ICUI. TheStreet upgraded shares of ICU Medical from a “c+” rating to a “b+” rating in a report on Monday, August 20th. ValuEngine upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Tuesday. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 28th. Finally, Zacks Investment Research cut shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Wednesday, July 11th. Two equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $337.00.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

See Also: 52-Week High/Low Prices For Stock Selection

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply